Patents Examined by Terra C. Gibbs
  • Modulation of apolipoprotein C-III expression
    Patent number: 9624496
    Abstract: Compounds, compositions and methods are provided for modulating the expression of apolipoprotein C-III. The compositions comprise oligonucleotides, targeted to nucleic acid encoding apolipoprotein C-III. Methods of using these compounds for modulation of apolipoprotein C-III expression and for diagnosis and treatment of disease associated with expression of apolipoprotein C-III are provided.
    Type: Grant
    Filed: April 29, 2016
    Date of Patent: April 18, 2017
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Rosanne M. Crooke, Mark J. Graham, Kenneth W. Dobie
  • Compositions and methods for cancer and cancer stem cell detection and elimination
    Patent number: 9611330
    Abstract: In alternative embodiments, the invention provides compositions and methods for inhibiting or ablating cancer stem cells. In alternative embodiments, the invention provides compositions and methods for inhibiting the action of double-stranded RNA-specific adenosine deaminases, or ADAR, enzymes. In alternative embodiments, the invention provides compositions and methods for treating, ameliorating or preventing diseases and conditions responsive to the inhibition of cell differentiation and/or self-renewal of dysfunctional cells, cancer cells, leukemia cells, hematopoietic stem cells or cancer stem cells, e.g., leukemia or Chronic Myeloid Leukemia (CML). In alternative embodiments, the invention provides compositions and methods for inhibiting a Sonic Hedgehog (Shh) pathway, e.g., by using a Smoothened (SMO) protein inhibitor.
    Type: Grant
    Filed: September 7, 2012
    Date of Patent: April 4, 2017
    Assignee: The Regents of the University of California
    Inventors: Catriona H. Jamieson, Qingfei Jiang, Kelly A. Frazer, Christian L. Barrett, Anil Sadarangani, Angela Court, Leslie Crews Robertson
  • Capsid-free AAV vectors, compositions, and methods for vector production and gene delivery
    Patent number: 9598703
    Abstract: An isolated linear nucleic acid molecule comprising in this order: a first adeno-associated virus (AAV) inverted terminal repeat (ITR), a nucleotide sequence of interest and a second AAV ITR, wherein said nucleic acid molecule is devoid of AAV capsid protein coding sequences. The said nucleic acid molecule can be applied to a host at repetition without eliciting an immune response. Methods for producing and purifying this nucleic acid molecule, and use of the same for therapeutic purposes are also provided.
    Type: Grant
    Filed: March 12, 2012
    Date of Patent: March 21, 2017
    Assignees: ASSOCIATION INSTITUT DE MYOLOGIE; UNIVERSITÉ PIERRE ET MARIE CURIE (PARIS 6); CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE; INSTITUT NATIONAL DE LA SANTÉ DE LAD RECHERCHE MÉDICALE, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, NATIONAL INSTITUTES OF HEALTH
    Inventors: Luis Garcia, Cyriaque Beley, Thomas Voit, Robert Michael Kotin, Lina Li
  • Gene amplification of coactivator CoAA and uses thereof
    Patent number: 9574240
    Abstract: It has been discovered that amplifications in the gene coactivator activator (CoAA) blocks stem cell differentiation and induces cancer stem cells. One embodiment provides compositions and methods for treating or alleviating one or more symptoms associated with cancer due to gene amplifications in CoAA. Another embodiment provides methods and compositions for detecting cancer due to gene amplifications in CoAA. Still another embodiment provides methods for identifying compounds, antibodies and nucleic acid molecules that are useful for treating cancer due to gene amplifications in CoAA. Preferably the disclosed compositions antagonize or interfere with the CoAA amplicons and the biological activity of CoAA and or splice variants thereof.
    Type: Grant
    Filed: October 24, 2014
    Date of Patent: February 21, 2017
    Inventor: Lan Ko
  • NGF aptamer and application thereof
    Patent number: 9567589
    Abstract: The present invention provides an aptamer binding to NGF and capable of forming a potential secondary structure represented by the formula (I): wherein N is one nucleotide selected from the group consisting of A, G, C, U and T, N11-N13, N21-N23, N32-N38 and N42-N48 are the same or different and each is a bond or 1 or 2 nucleotides selected from the group consisting of A, G, C, U and T, N14, N24, N31, N41, N39 and N49 are the same or different and each is one nucleotide selected from the group consisting of A, G, C, U and T, N14 and N24, N31 and N41, and N39 and N49 each form a Watson-Crick base pair, N11-N12-N13-N14 and N21-N22-N23-N24 are nucleotide sequences capable of forming a stem structure in combination, and N31-N32-N33-N34-N35-N36-N37-N38-N39 and N41-N42-N43-N44-N45-N46-N47-N48-N49 are nucleotide sequences capable of forming a stem structure in combination.
    Type: Grant
    Filed: September 28, 2012
    Date of Patent: February 14, 2017
    Assignees: RIBOMIC INC., FUJIMOTO PHARMACEUTICAL CORPORATION
    Inventors: Ling Jin, Hisanao Hiramatsu
  • Method of treating hyperlipidemia and atherosclerosis with miR-30C
    Patent number: 9556432
    Abstract: This disclosure provides a novel role for microRNA (miR) regulation of lipid metabolism via the MTP pathway, leading to reductions in apoB secretion and blood lipid levels. MiR regulation of the MTP pathway is shown herein to reduce hyperlipidemia and atherosclerosis in vivo. Therefore, inhibition of MTP expression and activity by miR regulation is identified as a new therapeutic target for treatment of cardiovascular disease and conditions or diseases associated with cardiovascular disease such as hyperlipidemia, atherosclerosis, and metabolic syndrome. Treatment of cardiovascular disease and associated conditions or diseases with the novel MTP inhibitors of the invention, such as miR-30c homologs or miR-30c agonists, reduces MTP-associated lipid production without side effects that occur with other methods of MTP inhibition.
    Type: Grant
    Filed: January 9, 2013
    Date of Patent: January 31, 2017
    Assignee: The Research Foundation for The State University of New York
    Inventors: Mahmood Hussain, James Soh
  • Targeting microRNAs for metabolic disorders
    Patent number: 9550996
    Abstract: Provided herein are methods and compositions for the treatment of metabolic disorders. Also provided herein are methods and compositions for the reduction of blood glucose level, the reduction of gluconeogenesis, the improvement of insulin resistance and the reduction of plasma cholesterol level. In certain embodiments, the methods comprise inhibiting the activity of miR-103. In certain embodiments, the methods comprise inhibiting the activity of miR-107. In certain embodiments, the activity of both miR-103 and miR-107 is inhibited. In certain embodiments, such methods comprise administering a compound comprising an oligonucleotide targeted to a microRNA.
    Type: Grant
    Filed: December 16, 2015
    Date of Patent: January 24, 2017
    Assignee: ETH Zurich
    Inventors: Markus Stoffel, Mirko Trajkovski
  • Method of promoting wound healing
    Patent number: 9545420
    Abstract: Disclosed is a method of promoting wound healing or wound closure. The method comprises administration of a miR-198 inhibitor and/or a follistatin-like-1 (FSTL1) polypeptide. Also disclosed are method of treating chronic cutaneous wounds, method of identifying a non-healing wound, use and a pharmaceutical composition comprising a miR-198 inhibitor and/or a follistatin-like-1 (FSTL1) polypeptide.
    Type: Grant
    Filed: July 29, 2013
    Date of Patent: January 17, 2017
    Assignee: Agency for Science, Technology and Research
    Inventor: Prabha Sampath
  • Replication factor C-40 (RFC40/RFC2) as a prognostic marker and target in estrogen positive and negative and triple negative breast cancer
    Patent number: 9546366
    Abstract: The present disclosure relates generally to cancer and particularly to breast cancer including estrogen sensitive, estrogen resistant and triple negative breast cancer (TNBC), and to methods of diagnosis and prognosis thereof and therapeutic intervention involving replication factor C 40 (RFC40). Methods and assays for evaluating breast cancer are provided. The disclosure also relates to inhibition or modulation of RFC40 in treatment or alleviation of cancer, including breast cancer. RFC40 inhibitors, including siRNAs, miRNAs, and shRNAs, which specifically affect cancer cells, particularly breast cancer cells, are provided.
    Type: Grant
    Filed: November 23, 2015
    Date of Patent: January 17, 2017
    Assignee: Raadysan Biotech, Inc.
    Inventor: Rakhee S. Gupte
  • Compositions and methods for treating amyotrophic lateral sclerosis
    Patent number: 9539307
    Abstract: The invention relates to pharmaceutical compositions, kits, methods, and uses for the treatment of amyotrophic lateral sclerosis. In particular, the invention relates to pharmaceutical compositions, kits, methods, and uses for the treatment of amyotrophic lateral sclerosis by decreasing the expression of a cytoplasmic granule toxin in astrocytes of a patient, or by increasing the expression of MHC class I in motor neurons of the patient.
    Type: Grant
    Filed: September 17, 2013
    Date of Patent: January 10, 2017
    Assignee: The Research Institute at Nationwide Children's Hospital
    Inventor: Brian Kaspar
  • Methods and compositions for malic enzyme 2 (ME2) as a target for cancer therapy
    Patent number: 9539323
    Abstract: The present invention relates to methods, compositions, and diagnostic tests for treating and diagnosing cancer and other related diseases that result in dysregulation of malic enzyme 2. In particular, the methods and compositions include combination therapy, such as with a combination of two or more ME2 inhibitors or a combination of an ME2 inhibitor and an anticancer agent.
    Type: Grant
    Filed: August 5, 2011
    Date of Patent: January 10, 2017
    Assignee: Beth Israel Deaconess Medical Center, Inc.
    Inventors: Vikas P. Sukhatme, Jian-Guo Ren
  • Methods of treating a metabolic syndrome by modulating heat shock protein (HSP) 90-?
    Patent number: 9533002
    Abstract: The invention provides methods of treatment of metabolic syndrome with HSP90 inhibitors, particularly HSP90? inhibitors. The invention provides methods of diagnosis and monitoring of metabolic syndrome using HSP90, particularly HSP90?, expression and activity level.
    Type: Grant
    Filed: May 24, 2013
    Date of Patent: January 3, 2017
    Assignee: Berg LLC
    Inventors: Niven Rajin Narain, Rangaprasad Sarangarajan, Vivek K. Vishnudas, Enxuan Jing
  • Compositions and methods to promote erythropoiesis
    Patent number: 9512430
    Abstract: Described herein are compositions and methods for enhancing erythropoiesis in an individual in need thereof. Specifically agents that decrease the expression of Exosc8, Exosc9, Dis3, Dis3L or Exosc10, such as inhibitory nucleic acid molecules, produce an increase in red blood cell production in the individual.
    Type: Grant
    Filed: July 3, 2014
    Date of Patent: December 6, 2016
    Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Emery H. Bresnick, Yoon A. Kang, Skye McIver
  • Co-activation of mTOR and STAT3 pathways to promote neuronal survival and regeneration
    Patent number: 9511036
    Abstract: Disclosed herein is a method of promoting sustained survival, sustained regeneration, in a lesioned mature neuron, sustained compensatory outgrowth in a neuron, or combinations thereof. The method comprises contacting the lesioned mature neuron with an effective amount of an inhibitor of PTEN and an effective amount of an inhibitor of SOCS3 to thereby promote survival and/or regeneration and/or compensatory outgrowth of the neuron. Therapeutic methods of treatment of a subject with a neuronal lesion by administration of a therapeutically effective amount of an inhibitor of PTEN and a therapeutically effective amount of an inhibitor of SOCS3, are also disclosed, as are pharmaceutical compositions and devices for use in the methods.
    Type: Grant
    Filed: November 1, 2012
    Date of Patent: December 6, 2016
    Assignee: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Zhigang He, Duo Jin, Fang Sun
  • Compositions and methods for inhibiting expression of the HAMP gene
    Patent number: 9506067
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the HAMP gene (HAMP gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the HAMP gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by HAMP gene expression and the expression of the HAMP gene using the pharmaceutical composition.
    Type: Grant
    Filed: June 19, 2015
    Date of Patent: November 29, 2016
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Tomoko Nakayama, Anke Geick, Pamela Tan, Herbert Y. Lin
  • Retinaldehyde mimetics and inhibitors of retinaldehyde dehydrogenase I in the treatment of disorders
    Patent number: 9504660
    Abstract: The technology described herein is directed to methods of treating, e.g. obesity by administering retinaldehyde increasing agents.
    Type: Grant
    Filed: February 1, 2013
    Date of Patent: November 29, 2016
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Jorge Plutzky, Florian Kiefer
  • Antisense polynucleotides to induce exon skipping and methods of treating dystrophies
    Patent number: 9499817
    Abstract: Antisense polynucleotides and their use in pharmaceutical compositions to induce exon skipping in targeted exons of the gamma sarcoglycan gene are provided, along with methods of preventing or treating dystrophic diseases such as Limb-Girdle Muscular Dystrophy. One aspect the disclosure provides an isolated antisense polynucleotide wherein the polynucleotide specifically hybridizes to an exon target region of a gamma sarcoglycan RNA, wherein the exon is selected from the group consisting of exon 4 (SEQ ID NO:1), exon 5 (SEQ ID NO: 2), exon 6 (SEQ ID NO: 3), exon 7 (SEQ ID NO: 4) and a combination thereof. In some embodiments, the antisense polynucleotide cannot form an RNase H substrate, and in further embodiments the antisense polynucleotide comprises a modified polynucleotide backbone.
    Type: Grant
    Filed: September 6, 2013
    Date of Patent: November 22, 2016
    Assignee: THE UNIVERSITY OF CHICAGO
    Inventor: Elizabeth McNally
  • Immunosuppression compound and treatment method
    Patent number: 9487786
    Abstract: A method and compound for suppressing an immune response in a mammalian subject, for the treatment or prevention of an autoimmune condition or transplantation rejection are disclosed. The compound is an antisense oligonucleotide analog compound having a targeting sequence complementary to a preprocessed CTLA-4 mRNA region identified by SEQ ID NO: 22 in SEQ ID NO: 1, spanning the splice junction between intron 1 and exon 2 of the preprocessed mRNA of the subject. The compound is effective, when administered to a subject, to form within host cells, a heteroduplex structure (i) composed of the preprocessed CTLA-4 mRNA and the oligonucleotide compound, (ii) characterized by a Tm of dissociation of at least 45° C., and (iii) resulting in an increased ratio of processed mRNA encoding ligand-independent CTLA-4 to processed mRNA encoding full-length CTLA-4.
    Type: Grant
    Filed: December 23, 2014
    Date of Patent: November 8, 2016
    Assignee: SAREPTA THERAPEUTICS, INC.
    Inventors: Dan V. Mourich, Patrick L. Iversen, Dwight D. Weller
  • Methods for the treatment of leber congenital amaurosis
    Patent number: 9487782
    Abstract: The present invention relates to a method for treating a Leber congenital amaurosis in a patient harboring the mutation c.2991+1655 A>G in the CEP290 gene, comprising the step of administering to said patient at least one antisense oligonucleotide complementary to nucleic acid sequence that is necessary for preventing splicing of the cryptic exon inserted into the mutant c.2291+1655 A>G CEP290 mRNA.
    Type: Grant
    Filed: November 18, 2014
    Date of Patent: November 8, 2016
    Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), CNRS (Centre National de la Recherche Scientifique), GENETHON, UNIVERSITE PARIS DESCARTES, ENSCP—Chimie ParisTech—Ecole Nationale Superieure de Chimie de Paris, Universite d'Evry-Val-d'Essonne, ASSISTANCE PUBLIQUE HOPITAUX DE PARIS
    Inventors: Jean-Michel Rozet, Antoine Kichler, Isabelle Perrault, Josseline Kaplan, Xavier Gerard, Daniel Scherman, M. Arnold Munnich
  • Compositions and methods for the diagnosis and therapy of BCL2-associated cancers
    Patent number: 9480699
    Abstract: Provided are methods and compositions for the treatment of cancers associated with overexpression of a BCL2 gene and/or gene product in a subject, and methods and compositions for the improvement of anti-cancer therapy, such as chemotherapy and radiation therapy. Also provided are methods for determining the efficacy of a cancer therapy in a subject, methods for diagnosing cancer, methods for assessing patient prognosis, and methods for inducing apoptosis of a cell.
    Type: Grant
    Filed: July 25, 2014
    Date of Patent: November 1, 2016
    Assignee: The Ohio State University Research Foundation
    Inventors: Carlo M. Croce, George A. Calin